Chronic osteomyelitis caused by multi-resistant Gram-negative bacteria: evaluation of treatment with newer quinolones after prolonged follow-up

被引:44
作者
Galanakis, N [1 ]
Giamarellou, H [1 ]
Moussas, T [1 ]
Dounis, E [1 ]
机构
[1] LAIKON GEN HOSP,DEPT ORTHOPAED,GR-11527 ATHENS,GREECE
关键词
D O I
10.1093/jac/39.2.241
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
We evaluated ciprofloxacin, ofloxacin and pefloxacin regimens for the treatment of chronic osteomyelitis due to Gram-negative multiresistant organisms. The study was open, nonrandomized and included 28, 21 and 16 patients, respectively. The 4-fluoroquinolone regimens were 1000 mg, 400 mg and 400-800 mg bd, for a mean duration of 137, 163 and 134 days, respectively. Pseudomonas aeruginosa was the most common pathogen, isolated in 33 individuals. Patients were followed clinically, bacteriologically and radiologically during treatment and for 2-5 years after discontinuation of therapy. Clinical outcome at the end of therapy was successful in 79%, 81% and 75%, improvement occurred in 11%, 10% and 19%, and the failure rate was 11%, 10% and 6%, while 11%, 5% and 6% relapsed, respectively. At the end of follow-up the bacterial eradication rate was 68%, 76% and 69%, respectively. Fluoroquinolone resistance emerged in 18%, 19% and 13% of ciprofloxacin, ofloxacin and pefloxacin recipients, respectively. The newer quinolones were safe and well tolerated and should be considered as the contemporary treatment of choice for chronic Gram-negative osteomyelitis, particularly whenever P. aeruginosa is implicated.
引用
收藏
页码:241 / 246
页数:6
相关论文
共 21 条
[1]   CEFTAZIDIME AS SINGLE-AGENT THERAPY FOR GRAM-NEGATIVE AEROBIC BACILLARY OSTEOMYELITIS [J].
BACH, MC ;
COCCHETTO, DM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (10) :1605-1608
[2]  
CHAPMAN SW, 1986, PRACTICAL APPROACH I, P440
[3]   ORAL CIPROFLOXACIN TREATMENT OF PSEUDOMONAS-AERUGINOSA OSTEOMYELITIS [J].
DAN, M ;
SIEGMANIGRA, Y ;
PITLIK, S ;
RAZ, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (05) :849-852
[4]   THE DIFFUSION OF PEFLOXACIN INTO BONE AND THE TREATMENT OF OSTEOMYELITIS [J].
DELLAMONICA, P ;
BERNARD, E ;
ETESSE, H ;
GARRAFFO, R .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1986, 17 :93-102
[5]   EVALUATION OF PEFLOXACIN, OFLOXACIN AND CIPROFLOXACIN IN THE TREATMENT OF 39 CASES OF CHRONIC OSTEOMYELITIS [J].
DELLAMONICA, P ;
BERNARD, E ;
ETESSE, H ;
GARRAFFO, R ;
DRUGEON, HB .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1989, 8 (12) :1024-1030
[6]   THE NEW QUINOLONES AND THEIR COMBINATIONS WITH OTHER AGENTS FOR THERAPY OF SEVERE INFECTIONS [J].
DESPLACES, N ;
GUTMANN, L ;
CARLET, J ;
GUIBERT, J ;
ACAR, JF .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1986, 17 :25-39
[7]  
FONG IW, 1985, RECENT ADV CHEMOTHER, P1614
[8]   OFLOXACIN VERSUS PARENTERAL THERAPY FOR CHRONIC OSTEOMYELITIS [J].
GENTRY, LO ;
RODRIGUEZGOMEZ, G .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (03) :538-541
[9]   ORAL CIPROFLOXACIN COMPARED WITH PARENTERAL ANTIBIOTICS IN THE TREATMENT OF OSTEOMYELITIS [J].
GENTRY, LO ;
RODRIGUEZ, GG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (01) :40-43
[10]   PEFLOXACIN VERSUS CEFTAZIDIME IN THE TREATMENT OF A VARIETY OF GRAM-NEGATIVE-BACTERIAL INFECTIONS [J].
GIAMARELLOU, H ;
PERDIKARIS, G ;
GALANAKIS, N ;
DAVOULOS, G ;
MANDRAGOS, K ;
SFIKAKIS, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (08) :1362-1367